EMCURE PHARMACEUTICALS
Back to Cashflow Statement
|
EMCURE PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹343 Cr | ₹-814 Cr | ₹-164 Cr | ₹-145 Cr | ₹-152 Cr |
What is the latest Cash Flow from Financing Activities ratio of EMCURE PHARMACEUTICALS ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹343 Cr |
| Mar2025 | ₹-814 Cr |
| Mar2024 | ₹-164 Cr |
| Mar2023 | ₹-145 Cr |
| Mar2022 | ₹-152 Cr |
How is Cash Flow from Financing Activities of EMCURE PHARMACEUTICALS Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹343 Cr | Positive | |
| Mar2025 | ₹-814 Cr | Negative | |
| Mar2024 | ₹-164 Cr | Negative | |
| Mar2023 | ₹-145 Cr | Negative | |
| Mar2022 | ₹-152 Cr | - | |
Compare Cash Flow from Financing Activities of peers of EMCURE PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| EMCURE PHARMACEUTICALS | ₹42,414.1 Cr | -0.2% | 20% | 62.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹454,914.0 Cr | 3.9% | 7.8% | 13% | Stock Analytics | |
| DIVIS LABORATORIES | ₹300,380.0 Cr | 11.5% | 20.6% | 68% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹181,169.0 Cr | 1% | 1.8% | 34.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,933.0 Cr | 1.1% | 11.8% | 14.9% | Stock Analytics | |
| CIPLA | ₹114,478.0 Cr | 1.1% | 7.9% | -6.3% | Stock Analytics | |
EMCURE PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| EMCURE PHARMACEUTICALS | -0.2% |
20% |
62.9% |
| SENSEX | 5.9% |
13% |
-1.9% |
You may also like the below Video Courses